Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Catabasis Pharmaceuticals Inc. (CATB)

6.19   0.08 (1.31%) 09-30 17:22
Open: 6.13 Pre. Close: 6.11
High: 6.29 Low: 6.06
Volume: 124,626 Market Cap: 118M
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The firm's primary focus is on treatments for rare diseases. The firm is also developing other product candidates for the treatment of lipid disorders. The firm's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The firm's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.352 - 6.388 6.388 - 6.427
Low: 5.981 - 6.02 6.02 - 6.063
Close: 6.036 - 6.104 6.104 - 6.178

Technical analysis

as of: 2020-09-30 4:39:37 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 8.50     One year: 9.75
Support: Support1: 5.55    Support2: 4.62
Resistance: Resistance1: 7.28    Resistance2: 8.35
Pivot: 6.54
Moving Average: MA(5): 6.18     MA(20): 6.47
MA(100): 6.58     MA(250): 5.75
MACD: MACD(12,26): -0.13     Signal(9): -0.07
Stochastic oscillator: %K(14,3): 29.66     %D(3): 34.92
RSI: RSI(14): 42.64
52-week: High: 8.59  Low: 2.74  Change(%): 22.6
Average Vol(K): 3-Month: 28193  10-Days: 19237

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
CATB has closed above bottom band by 13.5%. Bollinger Bands are 1.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 28 Sep 2020
Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society - BioSpace

Wed, 23 Sep 2020
Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society - Business Wire

Mon, 21 Sep 2020
Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer - Business Wire

Thu, 10 Sep 2020
Is Catabasis Pharmaceuticals (NASDAQ:CATB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Tue, 08 Sep 2020
Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences - Yahoo Finance

Fri, 04 Sep 2020
Should Catabasis Pharmaceuticals Inc (CATB) Stock Be in Your Portfolio? - InvestorsObserver

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 19
Shares Float (M) 19
% Held by Insiders 0.57
% Held by Institutions 40.87
Shares Short (K) 767
Shares Short P. Month (K) 784

Stock Financials

EPS -2.130
EPS Est This Year -1.390
EPS Est Next Year -1.100
Book Value (p.s.) 2.700
Profit Margin
Operating Margin
Return on Assets (ttm) -36.7
Return on Equity (ttm) -64.9
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.625
Qtrly Earnings Growth
Operating Cash Flow (M) -29
Levered Free Cash Flow (M) -18

Stock Valuations

PE Ratio -2.87
PEG Ratio
Price to Book value 2.26
Price to Sales
Price to Cash Flow -4.06

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.